EBV-specific TTCR-C4

EBV-specific TTCR-C4 is a **cell therapy product** based on donor-derived **Epstein-Barr virus (EBV)-specific CD8+ T cells** that have been genetically engineered to express a **Wilms Tumor Antigen 1 (WT1)-specific T-cell receptor (TCR C4)**. This therapy is designed to enhance anti-leukemia activity by leveraging both innate viral specificity and redirected tumor antigen targeting. The T cells are first selected for their specificity to EBV, then further modified to express the high-affinity WT1-specific TCR (C4). The therapeutic rationale is that these engineered T cells will persist longer due to their viral specificity and target leukemic cells expressing WT1, offering a dual mechanism of tumor targeting. The lead clinical indication has been for **relapsed or refractory acute myeloid leukemia (AML) post-allogeneic hematopoietic cell transplantation (HCT)**. In clinical trials, infusions of EBV-specific TTCR-C4 were well tolerated without dose-limiting toxicities or therapy-related serious adverse events. However, efficacy remains under evaluation, as data shows prolonged persistence of engineered T cells but no clear superiority in clinical outcomes over controls[3][4][8].